<DOC>
	<DOCNO>NCT00140673</DOCNO>
	<brief_summary>The main objective study : 1 ) In subset ( N = 20 000 ) , determine vaccine efficacy severe rotavirus ( RV ) gastroenteritis ( GE ) period start 2 week Dose 2 one year age . 2 ) In subject ( N = 60 000 ) , determine safety GSK Biologicals ' HRV vaccine respect definite intussusception ( IS ) within 31 day ( Day 0-Day 30 ) HRV vaccine dose .</brief_summary>
	<brief_title>A Study Test 2 Doses HRV Vaccine Healthy Infants .</brief_title>
	<detailed_description>The study two group : Group HRV Group Placebo . Two oral dos administer healthy infant 6-13 week age time Dose 1 , accord 0 , 1 2-month schedule . Routine EPI vaccination give discretion investigator accord local National Plans Immunisation schedule participate country . A minimum 2-week interval observe HRV vaccine OPV dose . Of total enrolled cohort 60 000 subject , 20 000 subject follow efficacy safety one year age 40 000 subject follow safety 30-90 day second HRV/placebo dose . A subset ( N = approximately 13 000 ) 20 000 subject follow efficacy safety 24 month age . From 20 000 subject follow efficacy safety , subset 100 subject per country ( center specific , except Finland ) provide two blood sample evaluate immunogenicity .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<criteria>Inclusion criterion : Healthy infant 613 week age time first study vaccination whose parent/guardian sign write informed consent whose parents/guardians comply requirement protocol ( e.g. , completion diary card , return followup visit ) Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine placebo , plan use study period Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . ( Topical steroid allow . ) Child unlikely remain study area duration study Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection History allergic disease reaction likely exacerbated component vaccine Administration immunoglobulins and/or blood product since birth plan administration study period Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract serious medical condition determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>13 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>